STEROID-ENHANCING SELECTIVE CASEIN KINASE INHIBITORS: FIRST IN CLASS NOVEL INHALED ANTI-ASTHMA AGENTS
Grant number: 1137171 | Funding period: 2018 - 2019
Chronic lung diseases reduce quality and duration of life of 0.5 billion globally (1 in 4 Australians). Current drugs fail to adequately reduce the decline in lung function. This development is based on the discovery of an enzyme pathway contributing to poor lung function. The project will identify the best doses of the drug and the best combinations with existing drugs to reduce the lung scarring and inflammation. These new findings support efforts to secure investment for clinical testing.